BioPharma Dive

@BioPharmaDive

We provide business journalism and in-depth insight into the most impactful news and trends shaping biotech and pharma. Sign up here:

Washington, D.C.
Vrijeme pridruživanja: srpanj 2013.

Medijski sadržaj

  1. 12. kol 2019.

    Shares in rose to their highest level in the past year as a favorable ruling makes Enbrel sales through 2029 more secure.

  2. 4. lis 2018.

    FDA could set record low for drug marketing warning letters — again

  3. 12. ruj 2018.

    The stock is down 90% today from the news.

  4. 7. kol 2018.

    Top headline from yesterday: Regeneron and Bluebird team up on immuno-oncology. Analysis of what the could deal mean:

  5. 4. kol 2018.

    Almirall focused on Seysara, an antibiotic for acne vulgaris that it predicts will earn between $150 million and $200 million in peak annual sales. Almirall will pay up to $650 million to in the deal.

  6. 7. pro 2017.

    BioPharma Dive Senior Editor Lisa LaMotta sat down with PwC to discuss the top issues we are going to see in 2018. Stay tuned for more on 12/12! @BioWriterChik

  7. 26. stu 2017.
  8. 30. ruj 2017.

    Positive Ph. 3 results for 's lead drug patisiran bring RNAi to the brink of becoming a medical reality

  9. 29. ruj 2017.

    Positive Ph. 3 results for 's lead drug patisiran bring RNAi to the brink of becoming a medical reality

  10. 5. ruj 2017.
  11. 5. ruj 2017.
  12. 5. ruj 2017.
  13. 22. velj 2017.

    BioPharma Dive Editor Lisa LaMotta met with immuno-oncology investor at . Watch it here:

  14. 17. pro 2016.

    Love BioPharma Dive? Become a Dive Insider and earn perks like this snazzy shirt! Learn more:

  15. 27. srp 2016.

    TauRx Alzheimer's drug flunks late-stage study

  16. 25. srp 2016.

    After scandal, China begins vaccine inspections nationwide

  17. 24. srp 2016.

    Report: US drug prices often higher than in other developed countries

  18. 24. srp 2016.

    Chinese team to test CRISPR in humans, jumping ahead of planned US study

  19. 24. srp 2016.

    Post-censures, Theranos ramps up compliance efforts

  20. 23. srp 2016.

    Chinese team to test CRISPR in humans, jumping ahead of planned US study

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·